Connectyx, based in Palm City, FL, is a biotech company focused on identifying, acquiring, and developing disease-modifying therapeutic drug candidates, with a particular emphasis on rare disease indications. With a unique business model and a team of experienced industry leaders, Connectyx aims to build a pipeline of first-in-class drugs that can address the unmet medical needs of patients. Currently, the company has nine ongoing programs in three therapeutic areas, all of which are focused on orphan indications but have the potential for future expansion into non-orphan indications.
Curative Biotechnology, a subsidiary of Connectyx, recently announced the nomination of Dr. Theresa Heah and Dr. Jeffrey Liebmann to its Board of Directors, further strengthening its leadership team. Additionally, the company has established a Japanese subsidiary to facilitate licensing transactions and asset acquisitions. Connectyx's stock price quotes are available, although they may be delayed and not real-time. As a forward-looking company, Connectyx is committed to advancing its strategy, operations, and financial position to deliver innovative solutions for unmet medical needs.
Generated from the website